Pre-existing anti-tumor immunity such as the presence of CD8+ tumor-infiltrating lymphocytes (CD8+ TILs), has also been reported to play an essential role in the activity of anti-PD-1/PD-L1 immunotherapy and in predicting therapeutic efficacy7–9. Here, CD8A is linked to neoplasm.